Patents Assigned to Neurotech USA, Inc.
-
Patent number: 11207266Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.Type: GrantFiled: September 6, 2019Date of Patent: December 28, 2021Assignee: Neurotech, USA, Inc.Inventors: Jeffrey Louis Goldberg, Cahil McGovern, Weng Tao, Konrad A. Kauper
-
Patent number: 10456356Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.Type: GrantFiled: May 27, 2016Date of Patent: October 29, 2019Assignee: Neurotech USA, Inc.Inventors: Jeffrey Louis Goldberg, Cahil McGovern, Weng Tao, Konrad Kauper
-
Patent number: 10195140Abstract: Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.Type: GrantFiled: November 7, 2017Date of Patent: February 5, 2019Assignee: Neurotech USA, Inc.Inventors: Cahil McGovern, Weng Tao, Konrad Kauper
-
Patent number: 10004804Abstract: The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases.Type: GrantFiled: June 16, 2015Date of Patent: June 26, 2018Assignee: Neurotech USA, Inc.Inventors: Vincent Ling, Arne M. Nystuen, Weng Tao, Paul Francis Stabila, Konrad A. Kauper
-
Patent number: 9925219Abstract: The invention provides multi-chamber encapsulated cell therapy cartridge devices that are capable of delivering biologically active molecules as well as methods of using these devices.Type: GrantFiled: September 10, 2014Date of Patent: March 27, 2018Assignee: Neurotech USA, Inc.Inventors: Konrad A. Kauper, John Fraser Mills, Megan Billings, Michael R. Rivera, Alline Monteiro Alcantara Lelis
-
Patent number: 9265814Abstract: The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.Type: GrantFiled: December 18, 2006Date of Patent: February 23, 2016Assignee: Neurotech USA, INC.Inventors: Konrad Kauper, Weng Tao, Paul Stabila
-
Patent number: 9149427Abstract: The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases.Type: GrantFiled: November 30, 2011Date of Patent: October 6, 2015Assignee: Neurotech USA, Inc.Inventors: Vincent Ling, Arne M. Nystuen, Weng Tao, Paul Stabila, Konrad Kauper
-
Publication number: 20150024024Abstract: Cells and cell lines that are genetically modified to express the hCox-2 enzyme, which results in the upregulation of prostaglandin F2 alpha (PGF2a) on the cells have been obtained. Encapsulated cell therapy devices containing such cells or cell lines that are capable of delivering PGF2a, as well as methods of using these devices to deliver PGF2a to the eye and to treat ophthalmic disorders in patients suffering therefrom are also described.Type: ApplicationFiled: April 21, 2010Publication date: January 22, 2015Applicant: Neurotech USA, Inc.Inventors: Weng Tao, Konrad Kauper, Paul Francis Stabila, Vincent Ling
-
Patent number: 7820195Abstract: The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.Type: GrantFiled: December 18, 2006Date of Patent: October 26, 2010Assignee: Neurotech USA, Inc.Inventors: Konrad Kauper, Paul Stabila, Weng Tao
-
Publication number: 20090269319Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.Type: ApplicationFiled: July 8, 2009Publication date: October 29, 2009Applicant: NEUROTECH USA, INC.Inventors: Weng Tao, David H. Rein, Brenda J. Dean, Paul F. Stabila, Moses B.I. Goddard
-
Publication number: 20090269389Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.Type: ApplicationFiled: July 7, 2009Publication date: October 29, 2009Applicant: NEUROTECH USA, INC.Inventors: Weng Tao, David H. Rein, Brenda J. Dean, Paul F. Stabila, Moses B.I. Goddard